Condition
Malignant Pleural Mesothelioma|Non-Small Cell Lung Cancer
Estimated Enrollment: 27
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: HREC/13/CRGH/199
Study First Received: January 5, 2015
Last Updated: April 5, 2017
Estimated Primary Completion Date: January 4, 2017
Primary Outcome Measures:
There is a composite primary outcome to establish maximum tolerated dose and dose limiting toxicities The MTD will be determined by the assessment of dose limiting toxicities.|to evaluate the effect of multiple dosing of TargomiRs|to detect early signs of efficacy|QOL assessment|ECOG PS change|Pulmonary function change
Sponsors and Collaborators:
Asbestos Diseases Research Foundation|EnGeneIC Limited
Website Link: https://ClinicalTrials.gov/show/NCT02369198
